United States  

Tiziana Life Sciences upbeat on potential for coronavirus treatment

Proactive Investors Thursday, 9 April 2020
US and UK listed biotech with three key monoclonal antibody treatments Has applied for a patent for possible coronavirus treatment Other products target liver cancer and autoimmune diseases   How it’s doing Shares have soared recently on the potential for Tiziana’s (LON:TILS) TZLS-501 to be useful for people severely ill with coronavirus-related complications. TZLS-501 is a class of monoclonal antibody (mAb) called an anti-interleukin-6 receptor, or anti-IL6R for short. On-the-ground testing in China has revealed anti-IL6R mAbs, currently approved for rheumatoid arthritis, has a role to play in treating patients. So, the country’s National Health Commission has recommended the use of Roche blockbuster, Actemra, for patients infected with COVID-19 with serious lung damage and elevated IL-6 levels. Other drugs in development  TZLS-501 is the current focus though last year Tiziana received top-line data from a phase IIa trial of its liver cancer treatment Milciclib as a monotherapy. A phase 1 trial of its anti-CD3 monoclonal antibody Foralumab delivered via a nasal spray also finished in January with no safety indications and the autoimmune drug being well-tolerated. Chairman Gabriele Cerrone has high hopes for its nasal delivery method as all autoimmune drugs currently are administered by injection.   What the boss says: Gabriele Cerrone, chairman “The drug [TZLS-501] works not by treating the virus but attacking inflammation in the lungs - it is attacking the two proteins causing this inflammation. As such, the chances that we will work against another future strain are very high. “The technology, we think, provides immediate relief thanks to the delivery speed”     Inflexion points Clinical trials get for coronavirus treatments Partner liver cancer and autoimmune drugs Delivery system proves effective for other treatments, opening up huge markets
0
shares
ShareTweetSavePostSend
 
Video Credit: CBS Dallas Digital - Published
News video: Coronavirus Disease 2019 (COVID-19) – Prevention & Treatment

Coronavirus Disease 2019 (COVID-19) – Prevention & Treatment 01:15

The Centers for Disease Control has a whole page of information dealing with Coronavirus. Katie Johnston reports.

You Might Like


Related videos from verified sources

Calls to one St. Louis women’s shelter increase 44 percent [Video]

Calls to one St. Louis women’s shelter increase 44 percent

There is a lot of talk about being safe at home right now, but one St. Louis women’s shelter wants everyone to understand not everyone can be safe at home.

Credit: KTVI     Duration: 02:17Published
With graduations being canceled or postponed, Missouri parents drop-off gifts to over 300 seniors [Video]

With graduations being canceled or postponed, Missouri parents drop-off gifts to over 300 seniors

Graduating high school is a moment every senior works towards. But due to the COVID-19 pandemic many may not have the chance to walk across the stage.

Credit: KTVI     Duration: 02:00Published
With potential food disruptions due to the COVID-19 pandemic, some are investing in resiliency gardens [Video]

With potential food disruptions due to the COVID-19 pandemic, some are investing in resiliency gardens

With food disruptions at grocery stores and supermarkets, a St. Louis gardener is encouraging others to consider a resiliency garden.

Credit: KTVI     Duration: 01:45Published

Related news from verified sources

Tiziana Life Sciences files patent application for potential coronavirus treatment

Tiziana Life Sciences PLC (LON:TILS)(NASDAQ:TLSA) revealed Monday it has filed a patent application for a coronavirus (COVID-19) treatment that combines...
Proactive Investors

Tiziana Life Sciences develops inhaler technology designed for rapid delivery of its coronavirus treatment

Tiziana Life Sciences PLC (NASDAQ:TLSA) has developed a handheld inhaler that will allow the rapid delivery of TZLS-501, its drug to treat inflammation of the...
Proactive Investors

Tiziana acquires nano-particle formulation of a drug that may help in the fight against forms of leukaemia and the coronavirus

Tiziana Life Sciences PLC (LON:TILS) (NASDAQ:TLSA) said it has acquired the slow release version of an antibiotic drug used to treat cancer and which could be...
Proactive Investors


Tweets about this